Satoshi Sugita
Kagoshima, 8908520, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective study.
Journal: BMC nephrology
Published: December 26, 2023
Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification.
Journal: BMC cancer
Published: September 25, 2023
microRNA-99a-5p induces cellular senescence in gemcitabine-resistant bladder cancer by targeting SMARCD1.
Journal: Molecular oncology
Published: September 13, 2021
Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Journal: Cancer science
Published: December 27, 2019
Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation.
Journal: Molecular oncology
Published: September 30, 2019
Potential tumor‑suppressive role of microRNA‑99a‑3p in sunitinib‑resistant renal cell carcinoma cells through the regulation of RRM2.
Journal: International journal of oncology
Published: September 19, 2018
Tumor‑suppressive microRNA‑223 targets WDR62 directly in bladder cancer.
Journal: International journal of oncology
Published: August 07, 2018
Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer.
Journal: British journal of cancer
Published: February 14, 2018
HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
Journal: International journal of oncology
Published: January 26, 2018
Last Updated: 09/26/2026